Ara
Toplam kayıt 17, listelenen: 11-17
Chlorogenic acid attenuates cisplatin-induced ovarian injury in rats
(Taylor & Francis Ltd., 2023)
The aim of this study was to determine the possible therapeutic effect of chlorogenic acid (CGA) on cisplatin (CDDP)-induced ovarian damage in rats. Rats were first exposed to CDDP (5 mg/kg) and then treated CGA (1.5 and ...
Ethyl pyruvate attenuates cisplatin-induced ovarian injury in rats via activating Nrf2 pathway
(Taylor & Francis Ltd., 2023)
Although cisplatin (CDDP) is an antineoplastic drug widely used for the treatment of various tumors, its toxicity on the reproductive system is a concern for patients. Ethyl pyruvate (EP) possesses potent antioxidant and ...
Agomelatine on cisplatin-induced nephrotoxicity via oxidative stress and apoptosis
(Springer, 2023)
Drug-induced nephrotoxicity is the greatest deterrent to the use of cisplatin, which is a frequently used chemotherapeutic with
proven efectiveness in cancer therapy. Agomelatine, which is used in the treatment of sleep ...
Alpha-pinene neutralizes cisplatin-induced reproductive toxicity in male rats through activation of Nrf2 pathway
(Springer, 2023)
Purpose Testicular toxicity is one of the most important side efects of cisplatin (CP) therapy. Alpha-pinene (AP) is a naturally occurring monoterpene with antioxidant character in plants. Here, we aimed to evaluate the ...
Evaluation of the therapeutic effects of arbutin on cisplatin-induced ovarian toxicity in rats through endoplasmic reticulum stress and Nrf2 pathway
(Elsevier, 2023)
Arbutin (ARB) is a glycosylated hydroquinone with potent antioxidant effects. Although cisplatin (CP) is widely
used in chemotherapy, its toxicity in healthy tissues, including ovotoxicity, is an insurmountable problem. ...
Cisplatin-based chemotherapy in elderly patients with advanced stage (IIIB and IV) non-small cell lung cancer patients
(SAP - Slovak Academic Press, spol. s.r.o., 2011)
Lung cancer continues to be the leading cause of cancer-related mortality and approximately 70% of patients present with locally advanced or metastatic disease at the time of diagnosis. More than 50% of lung cancer cases ...
Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
(2012)
Limited data exist concerning the long-term (?5 year) survival rates of patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) receiving chemotherapy. We aimed to determine the long-term results of cisplatin ...